[Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines.]

IF 0.9 4区 医学 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Revista Espanola De Salud Publica Pub Date : 2020-09-11
Pedro Armario, Carlos Brotons, Roberto Elosua, Maria Alonso de Leciñana, Almudena Castro, Albert Clarà, Olga Cortés, Ángel Díaz Rodriguez, María Herranz, Soledad Justo, Carlos Lahoz, Juan Pedro-Botet, Antonio Pérez Pérez, Rafael Santamaria, Ricard Tresserras, Susana Aznar Lain, Miguel Ángel Royo-Bordonada
{"title":"[Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines.]","authors":"Pedro Armario,&nbsp;Carlos Brotons,&nbsp;Roberto Elosua,&nbsp;Maria Alonso de Leciñana,&nbsp;Almudena Castro,&nbsp;Albert Clarà,&nbsp;Olga Cortés,&nbsp;Ángel Díaz Rodriguez,&nbsp;María Herranz,&nbsp;Soledad Justo,&nbsp;Carlos Lahoz,&nbsp;Juan Pedro-Botet,&nbsp;Antonio Pérez Pérez,&nbsp;Rafael Santamaria,&nbsp;Ricard Tresserras,&nbsp;Susana Aznar Lain,&nbsp;Miguel Ángel Royo-Bordonada","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We present the adaptation for Spain of the updated European Cardiovascular Prevention Guidelines. In this update, greater stress is laid on the population approach, and especially on the promotion of physical activity and healthy diet through dietary, leisure and active transport policies in Spain. To estimate vascular risk, note should be made of the importance of recalibrating the tables used, by adapting them to population shifts in the prevalence of risk factors and incidence of vascular diseases, with particular attention to the role of chronic kidney disease. At an individual level, the key element is personalised support for changes in behaviour, adherence to medication in high-risk individuals and patients with vascular disease, the fostering of physical activity, and cessation of smoking habit. Furthermore, recent clinical trials with PCSK9 inhibitors are reviewed, along with the need to simplify pharmacological treatment of arterial hypertension to improve control and adherence to treatment. In the case of patients with type 2 diabetes mellitus and vascular disease or high vascular disease risk, when lifestyle changes and metformin are inadequate, the use of drugs with proven vascular benefit should be prioritised. Lastly, guidelines on peripheral arterial disease and other specific diseases are included, as is a recommendation against prescribing antiaggregants in primary prevention.</p>","PeriodicalId":47152,"journal":{"name":"Revista Espanola De Salud Publica","volume":"94 ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2020-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Salud Publica","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

We present the adaptation for Spain of the updated European Cardiovascular Prevention Guidelines. In this update, greater stress is laid on the population approach, and especially on the promotion of physical activity and healthy diet through dietary, leisure and active transport policies in Spain. To estimate vascular risk, note should be made of the importance of recalibrating the tables used, by adapting them to population shifts in the prevalence of risk factors and incidence of vascular diseases, with particular attention to the role of chronic kidney disease. At an individual level, the key element is personalised support for changes in behaviour, adherence to medication in high-risk individuals and patients with vascular disease, the fostering of physical activity, and cessation of smoking habit. Furthermore, recent clinical trials with PCSK9 inhibitors are reviewed, along with the need to simplify pharmacological treatment of arterial hypertension to improve control and adherence to treatment. In the case of patients with type 2 diabetes mellitus and vascular disease or high vascular disease risk, when lifestyle changes and metformin are inadequate, the use of drugs with proven vascular benefit should be prioritised. Lastly, guidelines on peripheral arterial disease and other specific diseases are included, as is a recommendation against prescribing antiaggregants in primary prevention.

[西班牙跨学科血管预防委员会关于更新的欧洲心血管预防指南的声明]
我们提出适应西班牙更新的欧洲心血管预防指南。在这次更新中,更加强调人口方法,特别是通过西班牙的饮食、休闲和积极交通政策促进体育活动和健康饮食。为了估计血管风险,应注意重新校准所使用的表格的重要性,使其适应危险因素流行率和血管疾病发病率的人口变化,特别要注意慢性肾脏疾病的作用。在个人层面上,关键因素是对行为改变、高风险个体和血管疾病患者坚持服药、促进身体活动和戒烟习惯的个性化支持。此外,本文回顾了最近的PCSK9抑制剂临床试验,以及简化动脉高血压药物治疗以改善控制和治疗依从性的必要性。对于2型糖尿病合并血管疾病或高血管疾病风险的患者,当生活方式改变和二甲双胍不足时,应优先使用已证实对血管有益的药物。最后,包括外周动脉疾病和其他特定疾病的指南,以及在一级预防中反对处方抗聚集剂的建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Revista Espanola De Salud Publica
Revista Espanola De Salud Publica PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
2.00
自引率
0.00%
发文量
106
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信